HealthEquity Reports Second Quarter Ended July 31, 2024 Financial Results

Rhea-AI Summary

HealthEquity (NASDAQ: HQY) reported strong financial results for Q2 FY25, with revenue increasing 23% to $299.9 million. Net income rose to $35.8 million, or $0.40 per diluted share, while non-GAAP net income reached $76.3 million, or $0.86 per diluted share. Adjusted EBITDA grew 46% to $128.3 million.

The company saw significant growth in key metrics, with HSAs increasing 15% to 9.4 million and Total HSA Assets rising 27% to $29.5 billion. HealthEquity also announced a $300 million stock repurchase program and raised its fiscal year 2025 guidance, projecting revenue between $1.165 billion and $1.185 billion.

Positive

• Revenue increased 23% year-over-year to $299.9 million
• Non-GAAP net income grew 67% to $76.3 million
• Adjusted EBITDA rose 46% to $128.3 million, representing 43% of revenue
• HSAs increased 15% year-over-year to 9.4 million
• Total HSA Assets grew 27% to $29.5 billion
• Announced $300 million stock repurchase program
• Raised fiscal year 2025 guidance

Negative

• None.

Insights

Financial Analyst

HealthEquity's Q2 FY25 results demonstrate robust growth and financial strength. Revenue increased by 23% year-over-year to $299.9 million, while non-GAAP net income surged by 67% to $76.3 million. The company's core HSA business is thriving, with a 15% increase in HSAs and a 27% rise in Total HSA Assets.

The announcement of a $300 million stock repurchase program signals management's confidence in the company's future and commitment to shareholder value. This, coupled with the refinancing of credit facilities, provides HealthEquity with enhanced financial flexibility.

The improved full-year guidance reflects the company's strong momentum. However, investors should monitor the sustainability of this growth rate and potential impacts of market conditions on HSA investments.

Market Research Analyst

HealthEquity's performance indicates a growing demand for HSAs and consumer-directed benefits. The 15% increase in HSAs to 9.4 million and 27% growth in Total HSA Assets to $29.5 billion reflect a shift towards consumer-driven healthcare models.

The company's expansion of its platform to include Health Payment Accounts could further diversify its revenue streams and strengthen its market position. However, the competitive landscape in the HSA custodian space is intensifying and HealthEquity will need to continue innovating to maintain its leadership.

The 24% year-over-year increase in HSAs with investments suggests growing consumer sophistication in managing healthcare savings, a trend that could drive future growth for HealthEquity if sustained.

Announces $300 Million Stock Repurchase Program

Highlights of the second quarter include:

• Revenue of $299.9 million, an increase of 23% compared to $243.5 million in Q2 FY24.
• Net income of $35.8 million, compared to $10.6 million in Q2 FY24, with non-GAAP net income of $76.3 million, an increase of 67% compared to $45.6 million in Q2 FY24.
• Net income per diluted share of $0.40, compared to $0.12 in Q2 FY24, with non-GAAP net income per diluted share of $0.86, compared to $0.53 in Q2 FY24.
• Adjusted EBITDA of $128.3 million, an increase of 46% compared to $88.1 million in Q2 FY24.
• 9.4 million HSAs, an increase of 15% compared to Q2 FY24.
• Total HSA Assets of $29.5 billion, an increase of 27% compared to Q2 FY24.
• 16.3 million Total Accounts, including both HSAs and complementary CDBs, an increase of 9% compared to Q2 FY24.
  

DRAPER, Utah, Sept. 03, 2024 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ: HQY) ("HealthEquity" or the "Company"), the nation's largest health savings account ("HSA") custodian, today announced financial results for its second quarter ended July 31, 2024.

"Team Purple delivered an outstanding second quarter, increasing HSAs and HSA Assets by 15% and 27%, respectively, driven by strong growth in new HSAs from sales and the transition of the remaining BenefitWallet HSAs to the HealthEquity platform," said Jon Kessler, President and CEO of HealthEquity. "Momentum in both topline growth and margin expansion allows us to raise guidance, accelerate our platform investments, launch Health Payment Accounts and announce a $300 million share repurchase authorization."

Second quarter financial results

Revenue for the second quarter ended July 31, 2024 was $299.9 million, an increase of 23% compared to $243.5 million for the second quarter ended July 31, 2023. Revenue this quarter included: service revenue of $116.7 million, custodial revenue of $138.7 million, and interchange revenue of $44.5 million.

HealthEquity reported net income of $35.8 million, or $0.40 per diluted share, and non-GAAP net income of $76.3 million, or $0.86 per diluted share, for the second quarter ended July 31, 2024. The Company reported net income of $10.6 million, or $0.12 per diluted share, and non-GAAP net income of $45.6 million, or $0.53 per diluted share, for the second quarter ended July 31, 2023.

Adjusted EBITDA was $128.3 million for the second quarter ended July 31, 2024, an increase of 46% compared to the second quarter ended July 31, 2023. Adjusted EBITDA was 43% of revenue, compared to 36% for the second quarter ended July 31, 2023.

Account and asset metrics

HSAs as of July 31, 2024 were 9.4 million, an increase of 15% year over year, including 711,000 HSAs with investments, an increase of 24% year over year. Total Accounts as of July 31, 2024 were 16.3 million, including 6.9 million other consumer-directed benefits ("CDBs").

Total HSA Assets as of July 31, 2024 were $29.5 billion, an increase of 27% year over year. Total HSA Assets included $16.4 billion of HSA cash and $13.1 billion of HSA investments. Client-held funds, which are deposits held on behalf of our Clients to facilitate administration of our CDBs, and from which we generate custodial revenue, were $0.8 billion as of July 31, 2024.

Stock repurchase program

The Company announced that its Board of Directors authorized a common stock repurchase program. Under the program, the Company may purchase up to $300 million of its common stock, as market conditions warrant. The common stock may be repurchased at prices that the Company deems appropriate and subject to market conditions, applicable law and other factors deemed relevant in the Company's sole discretion. Such repurchases may be effected through open market purchases, privately negotiated transactions or otherwise, including repurchase plans that satisfy the conditions of Rule 10b5-1 under the Securities Exchange Act of 1934. The stock repurchase program does not obligate the Company to repurchase any dollar amount or number of shares of common stock, and the program may be suspended or discontinued at any time.

Refinancing of credit facilities

On August 23, 2024, the Company entered into a new credit agreement, pursuant to which it established a new five-year senior secured revolving credit facility in an aggregate principal amount of up to $1.0 billion. The Company borrowed $511.9 million under this new facility to refinance all outstanding obligations under its prior credit agreement, including both the revolving credit facility and term loan facility thereunder. The revolving credit facility may be used in the future for working capital and general corporate purposes, including the financing of acquisitions and other investments.

Business outlook

For the fiscal year ending January 31, 2025, management expects revenue of $1.165 billion to $1.185 billion. Its outlook for net income is between $94 million and $109 million, resulting in net income of $1.05 to $1.22 per diluted share. Its outlook for non-GAAP net income, calculated using the method described below, is between $265 million and $280 million, resulting in non-GAAP net income per diluted share of $2.98 to $3.14 (based on an estimated 89 million diluted weighted-average shares outstanding). Management expects Adjusted EBITDA of $458 million to $478 million.

See “Non-GAAP financial information” below for definitions of our Adjusted EBITDA and non-GAAP net income. A reconciliation of the non-GAAP financial measures used throughout this release to the most comparable GAAP financial measures is included with the financial tables at the end of this release.

Conference call

HealthEquity management will host a conference call at 4:30 pm (Eastern Time) on Tuesday, September 3, 2024 to discuss the fiscal 2025 second quarter financial results. The conference call will be accessible by dialing 1-833-630-1956, or 1-412-317-1837 for international callers, and referencing conference ID "HealthEquity." A live audio webcast of the call will be available on the investor relations section of our website at http://ir.healthequity.com.

Non-GAAP financial information

To supplement our financial information presented on a GAAP basis, we disclose non-GAAP financial measures, including Adjusted EBITDA, non-GAAP net income, and non-GAAP net income per diluted share.

• Adjusted EBITDA is earnings before interest, taxes, depreciation and amortization, amortization of acquired intangible assets, stock-based compensation expense, merger integration expenses, acquisition costs, gains and losses on equity securities, amortization of incremental costs to obtain a contract, costs associated with unused office space, and certain other non-operating items.
• Non-GAAP net income is calculated by adding back to GAAP net income before income taxes the following items: amortization of acquired intangible assets, stock-based compensation expense, merger integration expenses, acquisition costs, gains and losses on equity securities, costs associated with unused office space, and losses on extinguishment of debt, and subtracting a non-GAAP tax provision using a normalized non-GAAP tax rate.
• Non-GAAP net income per diluted share is calculated by dividing non-GAAP net income by diluted weighted-average shares outstanding.
  

Non-GAAP financial measures should be considered in addition to results prepared in accordance with GAAP and should not be considered as a substitute for, or superior to, GAAP results. We believe that these non-GAAP financial measures provide useful information to management and investors regarding certain financial and business trends relating to the Company's financial condition and results of operations. The Company cautions investors that non-GAAP financial information, by its nature, departs from GAAP; accordingly, its use can make it difficult to compare current results with results from other reporting periods and with the results of other companies. In addition, while amortization of acquired intangible assets is being excluded from non-GAAP net income, the revenue generated from those acquired intangible assets is not excluded. Whenever we use these non-GAAP financial measures, we provide a reconciliation of the applicable non-GAAP financial measure to the most closely applicable GAAP financial measure. Investors are encouraged to review the related GAAP financial measures and the reconciliation of the non-GAAP financial measures to their most directly comparable GAAP financial measure as detailed in the tables below.

About HealthEquity

HealthEquity and its subsidiaries administer HSAs and various other consumer-directed benefits for over 16 million accounts, working in close partnership with employers, benefits advisors, and health and retirement plan providers who share our unwavering commitment to our mission to save and improve lives by empowering healthcare consumers. Through cutting-edge solutions, innovation, and a relentless focus on improving health outcomes, we empower individuals to take control of their healthcare journey while ultimately enhancing their overall well-being. Learn more about our “Purple" service and approach at www.healthequity.com.

Forward-looking statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding our industry, business strategy, plans, goals and expectations concerning our markets and market position, product expansion, future operations, expenses and other results of operations, revenue, margins, profitability, acquisition synergies, future efficiencies, tax rates, capital expenditures, liquidity and capital resources and other financial and operating information. When used in this discussion, the words “may,” “believes,” “intends,” “seeks,” “aims,” “anticipates,” “plans,” “estimates,” “expects,” “should,” “assumes,” “continues,” “could,” “will,” “future” and the negative of these or similar terms and phrases are intended to identify forward-looking statements in this press release.

Forward-looking statements reflect our current expectations regarding future events, results or outcomes. These expectations may or may not be realized. Although we believe the expectations reflected in the forward-looking statements are reasonable, we can give you no assurance these expectations will prove to be correct. Some of these expectations may be based upon assumptions, data or judgments that prove to be incorrect. Actual events, results and outcomes may differ materially from our expectations due to a variety of known and unknown risks, uncertainties and other factors. Although it is not possible to identify all of these risks and factors, they include, among others, risks related to the following:

• our ability to adequately place and safeguard our custodial assets, or the failure of any of our depository or insurance company partners;
• our ability to compete effectively in a rapidly evolving healthcare and benefits administration industry;
• our dependence on the continued availability and benefits of tax-advantaged HSAs and other CDBs;
• our ability to successfully identify, acquire and integrate additional portfolio purchases or acquisition targets;
• the significant competition we face and may face in the future, including from those with greater resources than us;
• our reliance on the availability and performance of our technology and communications systems;
• recent and potential future cybersecurity breaches of our technology and communications systems and other data interruptions, including resulting costs and liabilities, reputational damage and loss of business;
• the current uncertain healthcare environment, including changes in healthcare programs and expenditures and related regulations;
• our ability to comply with current and future privacy, healthcare, tax, ERISA, investment adviser and other laws applicable to our business;
• our reliance on partners and third-party vendors for distribution and important services;
• our ability to develop and implement updated features for our technology platforms and communications systems and successfully manage our growth; and
• our reliance on our management team and key team members.

For a detailed discussion of these and other risk factors, please refer to the risks detailed in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the fiscal year ended January 31, 2024 and subsequent periodic and current reports. Past performance is not necessarily indicative of future results. We undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Investor Relations Contact
Richard Putnam
801-727-1000
rputnam@healthequity.com

HealthEquity, Inc. and subsidiaries
Condensed consolidated balance sheets

(in thousands, except par value)	July 31, 2024			January 31, 2024
	(unaudited)
Assets
Current assets
Cash and cash equivalents	$	326,893		$	403,979
Accounts receivable, net of allowance for doubtful accounts of $2,831 and $3,947 as of July 31, 2024 and January 31, 2024, respectively		108,454			104,893
Other current assets		60,280			48,564
Total current assets		495,627			557,436
Property and equipment, net		4,592			6,013
Operating lease right-of-use assets		46,484			48,380
Intangible assets, net		1,254,210			835,948
Goodwill		1,648,145			1,648,145
Other assets		65,408			67,868
Total assets	$	3,514,466		$	3,163,790
Liabilities and stockholders’ equity
Current liabilities
Accounts payable	$	10,562		$	12,041
Accrued compensation		37,072			49,608
Accrued liabilities		63,379			46,038
Operating lease liabilities		9,895			9,404
Total current liabilities		120,908			117,091
Long-term liabilities
Long-term debt, net of issuance costs		1,101,400			874,972
Operating lease liabilities, non-current		46,158			48,766
Other long-term liabilities		25,497			19,270
Deferred tax liability		63,466			68,670
Total long-term liabilities		1,236,521			1,011,678
Total liabilities		1,357,429			1,128,769
Commitments and contingencies
Stockholders’ equity
Preferred stock, $0.0001 par value, 100,000 shares authorized, no shares issued and outstanding as of July 31, 2024 and January 31, 2024, respectively		—			—
Common stock, $0.0001 par value, 900,000 shares authorized, 87,324 and 86,127 shares issued and outstanding as of July 31, 2024 and January 31, 2024, respectively		9			9
Additional paid-in capital		1,886,765			1,829,384
Accumulated earnings		270,263			205,628
Total stockholders’ equity		2,157,037			2,035,021
Total liabilities and stockholders’ equity	$	3,514,466		$	3,163,790

HealthEquity, Inc. and subsidiaries
Condensed consolidated statements of operations and comprehensive income (unaudited)

	Three months ended July 31,								Six months ended July 31,
(in thousands, except per share data)		2024				2023				2024				2023
Revenue
Service revenue	$	116,720			$	111,960			$	234,934			$	223,033
Custodial revenue		138,684				92,676				260,328				181,156
Interchange revenue		44,524				38,913				92,263				83,792
Total revenue		299,928				243,549				587,525				487,981
Cost of revenue
Service costs		76,915				76,904				159,262				157,777
Custodial costs		10,108				8,037				19,165				16,075
Interchange costs		8,853				6,943				17,908				13,994
Total cost of revenue		95,876				91,884				196,335				187,846
Gross profit		204,052				151,665				391,190				300,135
Operating expenses
Sales and marketing		21,525				19,123				45,019				39,058
Technology and development		58,580				54,767				114,670				107,959
General and administrative		32,260				27,825				70,496				53,363
Amortization of acquired intangible assets		30,981				23,166				56,526				46,332
Merger integration		1,777				2,044				3,920				5,502
Total operating expenses		145,123				126,925				290,631				252,214
Income from operations		58,929				24,740				100,559				47,921
Other expense
Interest expense		(15,427	)			(13,272	)			(27,222	)			(28,269	)
Other income, net		3,114				2,756				6,518				4,584
Total other expense		(12,313	)			(10,516	)			(20,704	)			(23,685	)
Income before income taxes		46,616				14,224				79,855				24,236
Income tax provision		10,794				3,643				15,220				9,561
Net income and comprehensive income	$	35,822			$	10,581			$	64,635			$	14,675
Net income per share:
Basic	$	0.41			$	0.12			$	0.74			$	0.17
Diluted	$	0.40			$	0.12			$	0.73			$	0.17
Weighted-average number of shares used in computing net income per share:
Basic		87,131				85,533				86,805				85,286
Diluted		88,646				86,341				88,606				86,356

HealthEquity, Inc. and subsidiaries
Condensed consolidated statements of cash flows (unaudited)

	Six months ended July 31,
(in thousands)		2024				2023
Cash flows from operating activities:
Net income	$	64,635			$	14,675
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		82,548				77,387
Stock-based compensation		53,594				38,277
Amortization of debt discount and issuance costs		1,428				1,461
Loss on extinguishment of debt		—				1,157
Deferred taxes		(5,204	)			(8,138	)
Changes in operating assets and liabilities:
Accounts receivable, net		(3,561	)			4,254
Other assets		(9,345	)			(8,526	)
Operating lease right-of-use assets		3,365				6,594
Accrued compensation		(12,706	)			(14,675	)
Accounts payable, accrued liabilities, and other current liabilities		7,267				3,970
Operating lease liabilities, non-current		(3,840	)			(8,175	)
Other long-term liabilities		(4,623	)			384
Net cash provided by operating activities		173,558				108,645
Cash flows from investing activities:
Purchases of software and capitalized software development costs		(25,329	)			(18,794	)
Purchases of property and equipment		(1,462	)			(590	)
Acquisitions of HSA portfolios		(452,241	)			—
Net cash used in investing activities		(479,032	)			(19,384	)
Cash flows from financing activities:
Proceeds from long-term debt		225,000				—
Principal payments on long-term debt		—				(54,375	)
Settlement of client-held funds obligation, net		(828	)			(161	)
Proceeds from exercise of common stock options		4,216				1,354
Net cash provided by (used in) financing activities		228,388				(53,182	)
Increase (decrease) in cash and cash equivalents		(77,086	)			36,079
Beginning cash and cash equivalents		403,979				254,266
Ending cash and cash equivalents	$	326,893			$	290,345

HealthEquity, Inc. and subsidiaries
Condensed consolidated statements of cash flows (unaudited) (continued)

	Six months ended July 31,
(in thousands)		2024				2023
Supplemental cash flow data:
Interest expense paid in cash	$	26,970			$	23,504
Income tax payments, net		13,471				15,113
Supplemental disclosures of non-cash investing and financing activities:
Purchases of software and capitalized software development costs included in accounts payable, accrued liabilities, or accrued compensation		3,370				3,228
Purchases of property and equipment included in accounts payable or accrued liabilities		70				300
Non-cash purchase consideration related to acquisitions of HSA portfolios		20,325				—
Exercise of common stock options receivable		—				50

Stock-based compensation expense (unaudited)

Total stock-based compensation expense included in the condensed consolidated statements of operations and comprehensive income is as follows:

	Three months ended July 31,						Six months ended July 31,
(in thousands)		2024			2023			2024			2023
Cost of revenue	$	2,934		$	4,393		$	7,459		$	7,999
Sales and marketing		3,850			3,478			8,173			6,257
Technology and development		6,454			4,283			12,394			9,175
General and administrative		8,336			7,919			25,568			14,846
Total stock-based compensation expense	$	21,574		$	20,073		$	53,594		$	38,277

Total Accounts (unaudited)

(in thousands, except percentages)	July 31, 2024		July 31, 2023		% Change			January 31, 2024
HSAs	9,383		8,164		15	%		8,692
New HSAs from sales - Quarter-to-date	187		156		20	%		497
New HSAs from sales - Year-to-date	382		290		32	%		949
New HSAs from acquisitions - Year-to-date	616		—		*			—
HSAs with investments	711		574		24	%		610
CDBs	6,898		6,831		1	%		7,006
Total Accounts	16,281		14,995		9	%		15,698
Average Total Accounts - Quarter-to-date	16,214		14,954		8	%		15,318
Average Total Accounts - Year-to-date	16,066		14,967		7	%		15,105

• Not meaningful
  
  

HSA Assets (unaudited)

(in millions, except percentages)	July 31, 2024			July 31, 2023			% Change			January 31, 2024
HSA cash	$	16,368		$	14,021		17	%		$	15,006
HSA investments		13,099			9,181		43	%			10,208
Total HSA Assets		29,467			23,202		27	%			25,214
Average daily HSA cash - Quarter-to-date		16,363			14,001		17	%			14,210
Average daily HSA cash - Year-to-date		15,875			14,048		13	%			14,071

Client-held funds (unaudited)

(in millions, except percentages)	July 31, 2024			July 31, 2023			% Change			January 31, 2024
Client-held funds	$	817		$	811		1	%		$	842
Average daily Client-held funds - Quarter-to-date		860			891		(3)%				791
Average daily Client-held funds - Year-to-date		850			896		(5)%				845

Reconciliation of net income to Adjusted EBITDA (unaudited)

	Three months ended July 31,								Six months ended July 31,
(in thousands)		2024				2023				2024				2023
Net income	$	35,822			$	10,581			$	64,635			$	14,675
Interest income		(3,103	)			(2,484	)			(6,984	)			(4,082	)
Interest expense		15,427				13,272				27,222				28,269
Income tax provision		10,794				3,643				15,220				9,561
Depreciation and amortization		12,629				15,180				26,022				31,055
Amortization of acquired intangible assets		30,981				23,166				56,526				46,332
Stock-based compensation expense		21,574				20,073				53,594				38,277
Merger integration expenses		1,777				2,044				3,920				5,502
Amortization of incremental costs to obtain a contract		1,681				1,350				3,313				2,654
Costs associated with unused office space		806				1,286				1,596				2,302
Other		(101	)			—				658				153
Adjusted EBITDA	$	128,287			$	88,111			$	245,722			$	174,698

Reconciliation of net income outlook to Adjusted EBITDA outlook (unaudited)

	Outlook for the year ending
(in millions)	January 31, 2025
Net income	$94 - 109
Interest income	(13)
Interest expense	60
Income tax provision	31 - 36
Depreciation and amortization	50
Amortization of acquired intangible assets	112
Stock-based compensation expense	99
Merger integration expenses	13
Amortization of incremental costs to obtain a contract	7
Costs associated with unused office space	4
Other expense	1
Adjusted EBITDA	$458 - 478

Reconciliation of net income to non-GAAP net income (unaudited)

	Three months ended July 31,						Six months ended July 31,
(in thousands, except per share data)		2024			2023			2024			2023
Net income	$	35,822		$	10,581		$	64,635		$	14,675
Income tax provision		10,794			3,643			15,220			9,561
Income before income taxes - GAAP		46,616			14,224			79,855			24,236
Non-GAAP adjustments:
Amortization of acquired intangible assets		30,981			23,166			56,526			46,332
Stock-based compensation expense		21,574			20,073			53,594			38,277
Merger integration expenses		1,777			2,044			3,920			5,502
Costs associated with unused office space		806			1,286			1,596			2,302
Loss on extinguishment of debt		—			—			—			1,157
Total adjustments to income before income taxes - GAAP		55,138			46,569			115,636			93,570
Income before income taxes - Non-GAAP		101,754			60,793			195,491			117,806
Income tax provision - Non-GAAP (1)		25,439			15,199			48,873			29,452
Non-GAAP net income		76,315			45,594			146,618			88,354
Diluted weighted-average shares		88,646			86,341			88,606			86,356
GAAP net income per diluted share	$	0.40		$	0.12		$	0.73		$	0.17
Non-GAAP net income per diluted share	$	0.86		$	0.53		$	1.65		$	1.02

(1)   The Company utilizes a normalized non-GAAP tax rate to provide better consistency across the interim reporting periods within a given fiscal year by eliminating the effects of non-recurring and period-specific items, which can vary in size and frequency, and which are not necessarily reflective of the Company’s longer-term operations. The normalized non-GAAP tax rate applied to each period presented was 25%. The Company may adjust its non-GAAP tax rate as additional information becomes available and in conjunction with any other significant events occurring that may materially affect this rate, such as merger and acquisition activity, changes in business outlook, or other changes in expectations regarding tax regulations.

Reconciliation of net income outlook to non-GAAP net income outlook (unaudited)

	Outlook for the year ending
(in millions, except per share data)	January 31, 2025
Net income	$94 - 109
Income tax provision	31 - 36
Income before income taxes - GAAP	125 - 145
Non-GAAP adjustments:
Amortization of acquired intangible assets	112
Stock-based compensation expense	99
Merger integration expenses	13
Costs associated with unused office space	4
Total adjustments to income before income taxes - GAAP	228
Income before income taxes - Non-GAAP	353 - 373
Income tax provision - Non-GAAP (1)	88 - 93
Non-GAAP net income	$265 - 280
Diluted weighted-average shares	89
GAAP net income per diluted share (2)	$1.05 - 1.22
Non-GAAP net income per diluted share (2)	$2.98 - 3.14

(1)   The Company utilizes a normalized non-GAAP tax rate to provide better consistency across the interim reporting periods within a given fiscal year by eliminating the effects of non-recurring and period-specific items, which can vary in size and frequency, and which are not necessarily reflective of the Company’s longer-term operations. The normalized non-GAAP tax rate applied to each period presented was 25%. The Company may adjust its non-GAAP tax rate as additional information becomes available and in conjunction with any other significant events occurring that may materially affect this rate, such as merger and acquisition activity, changes in business outlook, or other changes in expectations regarding tax regulations.

(2)   GAAP and Non-GAAP net income per diluted share may not calculate due to rounding.

Certain terms

Term	Definition
HSA	A financial account through which consumers spend and save long-term for healthcare on a tax-advantaged basis.
CDB	Consumer-directed benefits offered by employers, including flexible spending and health reimbursement arrangements (“FSAs” and “HRAs”), Consolidated Omnibus Budget Reconciliation Act (“COBRA”) administration, commuter and other benefits.
HSA member	Consumers with HSAs that we serve.
Total HSA Assets	HSA members’ custodial cash assets held by our federally insured depository partners and our insurance company partners. Total HSA Assets also includes HSA members' investments in mutual funds through our custodial investment fund partner.
Client	Our employer clients.
Total Accounts	The sum of HSAs and CDBs on our platforms.
Client-held funds	Deposits held on behalf of our Clients to facilitate administration of our CDBs.
Network Partner	Our health plan partners, benefits administrators, and retirement plan recordkeepers.
Adjusted EBITDA	Earnings before interest, taxes, depreciation and amortization, amortization of acquired intangible assets, stock-based compensation expense, merger integration expenses, acquisition costs, gains and losses on equity securities, amortization of incremental costs to obtain a contract, costs associated with unused office space, and certain other non-operating items.
Non-GAAP net income	Calculated by adding back to GAAP net income before income taxes the following items: amortization of acquired intangible assets, stock-based compensation expense, merger integration expenses, acquisition costs, gains and losses on equity securities, costs associated with unused office space, and losses on extinguishment of debt, and subtracting a non-GAAP tax provision using a normalized non-GAAP tax rate.
Non-GAAP net income per diluted share	Calculated by dividing non-GAAP net income by diluted weighted-average shares outstanding.

FAQ

What was HealthEquity's revenue for Q2 FY25?

HealthEquity's revenue for Q2 FY25 was $299.9 million, a 23% increase compared to $243.5 million in Q2 FY24.

How much did HealthEquity's HSAs grow in Q2 FY25?

HealthEquity's HSAs grew by 15% year-over-year, reaching 9.4 million in Q2 FY25.

What is the size of HealthEquity's new stock repurchase program?

HealthEquity announced a $300 million stock repurchase program.

What is HealthEquity's revenue guidance for fiscal year 2025?

HealthEquity expects revenue between $1.165 billion and $1.185 billion for fiscal year 2025.

How much did HealthEquity's Total HSA Assets grow in Q2 FY25?

HealthEquity's Total HSA Assets grew by 27% year-over-year, reaching $29.5 billion in Q2 FY25.